Natera, Inc. (NASDAQ:NTRA) Shares Acquired by Creative Planning

Creative Planning lifted its position in shares of Natera, Inc. (NASDAQ:NTRA) by 18.3% in the 3rd quarter, according to its most recent filing with the Securities & Exchange Commission. The fund owned 5,833 shares of the medical research company’s stock after buying an additional 904 shares during the quarter. Creative Planning’s holdings in Natera were worth $740,000 at the end of the most recent quarter.

Other hedge funds and other institutional investors have also made changes to their positions in the company. SG Americas Securities LLC increased its position in Natera by 1,073.1% during the 2nd quarter. SG Americas Securities LLC now owns 65,730 shares of the medical research company’s stock worth $7,118,000 after purchasing an additional 60,127 shares in the last quarter. Russell Investments Group Ltd. increased its position in Natera by 15.1% during the 1st quarter. Russell Investments Group Ltd. now owns 74,460 shares of the medical research company’s stock worth $6,810,000 after purchasing an additional 9,781 shares in the last quarter. Natixis purchased a new stake in Natera during the 1st quarter worth about $758,000. Baader Bank Aktiengesellschaft purchased a new stake in Natera during the 2nd quarter worth about $478,000. Finally, Sumitomo Mitsui Trust Holdings Inc. purchased a new stake in Natera in the 1st quarter valued at about $33,956,000. Institutional investors and hedge funds own 99.90% of the company’s stock.

Insider Buying and Selling

In other Natera news, CFO Michael Burkes Brophy sold 1,866 shares of the company’s stock in a transaction that occurred on Thursday, October 31st. The stock was sold at an average price of $126.45, for a total value of $235,955.70. Following the transaction, the chief financial officer now directly owns 68,851 shares of the company’s stock, valued at $8,706,208.95. This represents a 0.00 % decrease in their position. The sale was disclosed in a document filed with the SEC, which is available at the SEC website. In other news, insider Jonathan Sheena sold 2,700 shares of the business’s stock in a transaction that occurred on Monday, August 12th. The stock was sold at an average price of $113.82, for a total value of $307,314.00. Following the completion of the sale, the insider now directly owns 299,441 shares in the company, valued at approximately $34,082,374.62. The trade was a 0.00 % decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, CFO Michael Burkes Brophy sold 1,866 shares of the business’s stock in a transaction that occurred on Thursday, October 31st. The shares were sold at an average price of $126.45, for a total value of $235,955.70. Following the completion of the sale, the chief financial officer now owns 68,851 shares of the company’s stock, valued at $8,706,208.95. This trade represents a 0.00 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last ninety days, insiders have sold 50,164 shares of company stock valued at $6,157,291. Corporate insiders own 7.60% of the company’s stock.

Natera Stock Performance

Natera stock opened at $124.16 on Monday. The stock’s 50 day moving average price is $123.40 and its 200 day moving average price is $112.38. The firm has a market capitalization of $15.36 billion, a PE ratio of -50.68 and a beta of 1.53. The company has a debt-to-equity ratio of 0.34, a quick ratio of 4.01 and a current ratio of 4.14. Natera, Inc. has a one year low of $40.17 and a one year high of $133.54.

Natera (NASDAQ:NTRA) last released its quarterly earnings results on Thursday, August 8th. The medical research company reported ($0.30) EPS for the quarter, topping the consensus estimate of ($0.69) by $0.39. The firm had revenue of $413.35 million for the quarter, compared to analyst estimates of $343.00 million. Natera had a negative return on equity of 36.74% and a negative net margin of 21.47%. Natera’s revenue for the quarter was up 58.1% on a year-over-year basis. During the same period in the previous year, the company posted ($0.97) EPS. As a group, sell-side analysts expect that Natera, Inc. will post -1.96 EPS for the current fiscal year.

Analyst Ratings Changes

Several analysts have commented on NTRA shares. The Goldman Sachs Group lifted their price target on Natera from $125.00 to $140.00 and gave the company a “buy” rating in a report on Wednesday, October 16th. BTIG Research lifted their price target on Natera from $125.00 to $135.00 and gave the company a “buy” rating in a report on Friday, August 9th. Robert W. Baird lifted their price target on Natera from $117.00 to $120.00 and gave the company an “outperform” rating in a report on Friday, August 9th. Piper Sandler restated an “overweight” rating and issued a $150.00 price target on shares of Natera in a report on Friday, September 13th. Finally, Stephens restated an “overweight” rating and issued a $125.00 price target on shares of Natera in a report on Friday, August 9th. One analyst has rated the stock with a sell rating and sixteen have given a buy rating to the company. Based on data from MarketBeat, the company currently has an average rating of “Moderate Buy” and a consensus target price of $125.69.

Natera Company Profile

Natera, Inc, a diagnostics company, develops and commercializes molecular testing services worldwide. Its products include Panorama, a non-invasive prenatal test that screens for chromosomal abnormalities of a fetus, as well as in twin pregnancies; Horizon carrier screening test for individuals and couples determine if they are carriers of genetic variations that cause certain genetic conditions; Vistara single-gene NIPT screens for 25 single-gene disorders that cause severe skeletal, cardiac, and neurological conditions; Spectrum, preimplantation genetic tests for couples undergoing IVF; Anora that analyzes miscarriage tissue from women; Empower, a hereditary cancer screening test; and non-invasive prenatal paternity product, which allows a couple to establish paternity without waiting for the child to be born.